Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRAP1 | Q12931 | 14/20 | 0.47 |
| ▸ | HSP90B1 | P14625 | 7/20 | 0.46 |
| ▸ | HSP90AA1 | P07900 | 3/20 | 0.41 |
| ▸ | RXRA | P19793 | 1/20 | 0.40 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.40 |
| ▸ | MAOB | P27338 | 1/20 | 0.39 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL383689 | 0.93 | TRAP1 (0.46) | TRAP1HSP90B1HSP90AA1HSP90AB1MAOB | |
| SCHEMBL10256155 | 0.85 | TRAP1 (0.44) | TRAP1HSP90B1RXRA | |
| SCHEMBL12659989 | 0.85 | TRAP1 (0.50) | TRAP1HSP90B1HSP90AA1RXRAHSP90AB1 | |
| SCHEMBL10256200 | 0.85 | TRAP1 (0.43) | TRAP1HSP90B1RXRASLC6A9 | |
| SCHEMBL383146 | 0.84 | SLC6A9 (0.41) | TRAP1HSP90B1HSP90AA1RXRAHSP90AB1 | |
| SCHEMBL383682 | 0.83 | TRAP1 (0.48) | TRAP1HSP90B1HSP90AA1HSP90AB1SLC6A9 | |
| SCHEMBL12660067 | 0.82 | PTGER1 (0.40) | TRAP1HSP90B1HSP90AA1SLC6A9 | |
| SCHEMBL15000764 | 0.82 | NAMPT (0.42) | TRAP1HSP90B1HSP90AA1RXRAHSP90AB1 | |
| SCHEMBL10256156 | 0.81 | BCHE (0.44) | TRAP1HSP90B1 | |
| SCHEMBL15000765 | 0.81 | TMEM97 (0.38) | TRAP1HSP90B1HSP90AA1MAOBSLC6A9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9914719-B2 | Hydroxybenzamide derivatives and their use as inhibitors of HSP90 | ASTEX THERAPEUTICS LTD. (GB) | 2018-03-13 | — | — | US | disclosed |
| US-20150045362-A1 | Hydroxybenzamide Derivatives And Their Use As Inhibitors Of HSP90 | ASTEX THERAPEUTICS LTD. (GB) | 2015-02-12 | — | — | US | disclosed |
| US-8883790-B2 | Pharmaceutical combinations | ASTEX THERAPEUTICS LIMITED (GB) | 2014-11-11 | — | — | US | disclosed |
| US-8530469-B2 | Therapeutic combinations of hydroxybenzamide derivatives as inhibitors of HSP90 | ASTEX THERAPEUTICS LTD. (GB) | 2013-09-10 | — | — | US | disclosed |
| US-20120251545-A1 | Therapeutic Combinations Of Hydroxybenzamide Derivatives As Inhibitors Of HSP90 | ASTEX THERAPEUTICS LIMITED (GB) | 2012-10-04 | — | — | US | disclosed |
| US-8106057-B2 | Dihydroxyphenyl isoindolylmethanones | ASTEX THERAPEUTICS, LTD. (GB) | 2012-01-31 | — | — | US | disclosed |
| US-20110105501-A1 | PHARMACEUTICAL COMBINATIONS | ASTEX THERAPEUTICS LIMITED (GB) | 2011-05-05 | — | — | US | disclosed |
| US-20100286167-A1 | DIHYDROXYPHENYL ISOINDOLYLMETHANONES | ASTEX THERAPEUTICS LTD. (GB) | 2010-11-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100286167-A1 | DIHYDROXYPHENYL ISOINDOLYLMETHANONES | HSP90AA1, HSP90AB1, HSP90AB2P | TRAP1 14/4885HSP90B1 12/4885HSP90AA1 1/4885 |
| US-20150045362-A1 | Hydroxybenzamide Derivatives And Their Use As Inhibitors Of HSP90 | HSP90AB1, HSP90AB2P, HSP90AA1 | TRAP1 34/4885HSP90B1 5/4885HSP90AA1 3/4885 |
| US-20110105501-A1 | PHARMACEUTICAL COMBINATIONS | GSK3B, CDK1, GSK3A | TRAP1 1626/4885HSP90B1 86/4885HSP90AA1 105/4885 |
| US-20120251545-A1 | Therapeutic Combinations Of Hydroxybenzamide Derivatives As Inhibitors Of HSP90 | HSP90AB1, HSP90AB2P, HSP90AA1 | TRAP1 26/4885HSP90B1 5/4885HSP90AA1 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.